Eli Lilly and Company (NYSE:LLY) is Wick Capital Partners LLC's 4th Largest Position

Wick Capital Partners LLC lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 14,364.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,267 shares of the company's stock after purchasing an additional 55,878 shares during the quarter. Eli Lilly and Company accounts for about 7.4% of Wick Capital Partners LLC's holdings, making the stock its 4th largest holding. Wick Capital Partners LLC's holdings in Eli Lilly and Company were worth $43,438,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Highline Wealth Partners LLC increased its position in Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. boosted its position in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $48,000. Compass Financial Services Inc purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $58,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 3.9 %

Shares of NYSE:LLY traded up $31.00 on Friday, reaching $825.10. The company had a trading volume of 6,056,616 shares, compared to its average volume of 3,482,066. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $782.34 billion, a PE ratio of 70.46, a PEG ratio of 1.40 and a beta of 0.51. The firm's 50 day simple moving average is $826.90 and its 200-day simple moving average is $816.98. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 EPS. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on LLY. Truist Financial upped their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Thursday. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,002.80.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.